IAVI

Translating scientific discoveries into affordable, accessible public health solutions

aka International AIDS Vaccine Initiative   |   New York, NY   |  http://www.iavi.org

Mission

IAVI is a nonprofit scientific research organization dedicated to addressing urgent, unmet global health challenges including HIV and tuberculosis. Our mission is to translate scientific discoveries into affordable, accessible public health solutions for the people who need them most.

Ruling year info

1996

Principal Officer

Dr. Mark B Feinberg

Chief Operating Officer

Ana Cespedes

Main address

125 Broad Street 9th Floor

New York, NY 10004 USA

Show more addresses

EIN

13-3870223

NTEE code info

AIDS (G81)

AIDS (H81)

IRS filing requirement

This organization is required to file an IRS Form 990 or 990-EZ.

Sign in or create an account to view Form(s) 990 for 2019, 2018 and 2017.
Register now

Communication

Blog

Programs and results

What we aim to solve

This profile needs more info.

If it is your nonprofit, add a problem overview.

Login and update

Our programs

SOURCE: Self-reported by organization

What are the organization's current programs, how do they measure success, and who do the programs serve?

Discovery

IAVI’s vaccine discovery and development laboratories are focused on identifying ways to generate protective immune responses against HIV and other infectious diseases, characterizing and optimizing antibodies as prevention and treatment products, and addressing other unmet global health needs. In doing this wide-ranging work, IAVI researchers collaborate closely with other innovators across the global health research landscape.

In 2008, IAVI established the Vaccine Design and Development Laboratory (DDL) to facilitate the design and development of viral vectors for vaccines. Scientists at the DDL engineer natural viruses to deliver vaccine immunogens with the goal of generating long-lasting antiviral immune responses. The DDL team uses the vesicular stomatitis virus (VSV) as a vector to develop vaccine candidates for HIV and emerging infectious diseases such as Lassa fever, Marburg virus diseases, and COVID-19.

Since 2009, due to the efforts of the IAVI Neutralizing Antibody Center (NAC) at Scripps Research and other institutions, hundreds of broadly neutralizing antibodies (bnAbs) have been isolated from volunteers with HIV. The structures of some of the most potent of these antibodies and their targets on the virus have also been solved. NAC scientists are now using these discoveries to inform the design of novel HIV vaccine candidates and are using advances in antibody science to develop antibodies to prevent and treat other diseases.

The HIV Vaccine Translational Research (HVTR) Laboratory at the Translational Health Science and Technology Institute (THSTI) NCR Biotech Science Cluster in Faridabad, Haryana, India, designs and evaluates preventive HIV vaccines. As a NAC-collaborating center of excellence, the laboratory plays a crucial role in spurring indigenous antibody discovery and preclinical development efforts and promoting industry collaboration on promising prevention products.

The IAVI Human Immunology Laboratory (HIL), based at Imperial College London, serves as the clinical immunology reference laboratory for IAVI and its research partners worldwide. The HIL specializes in the analysis of immune responses from studies and clinical trials by IAVI and its partners, serves as a central repository for samples collected from clinical and epidemiology research studies, and plays a crucial role in strengthening existing scientific capabilities in affiliated African and Indian laboratories.

Population(s) Served
People with HIV/AIDS
Economically disadvantaged people

IAVI develops vaccine candidates and other biomedical innovations and manages clinical research with partners in academic, biotechnology, pharmaceutical, and government institutions. IAVI also provides translational research services and support to other organizations in the field, assisting them with the complex process of transitioning innovations from the laboratory into clinical trials. This includes providing assistance with manufacturing protocols and clinical and regulatory filings.

Product Development Center
In 2013, the Bill & Melinda Gates Foundation (BMGF) awarded a grant to IAVI to create the Vaccine Product Development Center (VxPDC) to assist investigators affiliated with BMGF’s Collaboration for AIDS Vaccine Discovery with the complex process of transitioning vaccine candidates from the laboratory to the clinic. Subsequently, IAVI expanded the Product Development Center (PDC) in recognition of efforts beyond vaccines and extending this translational expertise to other partners — whether academic, nonprofit, government, or industry — that are advancing new biomedical interventions. The PDC fills a critical gap in the development process for new vaccines and other biomedical innovations. Today, investigators from the U.S. National Institutes of Health and European funding partners are among those who utilize IAVI’s PDC.


The PDC provides:
- A team of pharmaceutical development experts who collectively have advanced hundreds of projects through global regulatory agencies.
- An extensive network of Contract Research Organizations, Contract Manufacturing Organizations, and technology partners to accelerate development and minimize risk.
- Access to clinical research networks around the world, including in Africa and India.
- Over 20 years of HIV vaccine development experience from projects using a wide range of technology platforms.

Population(s) Served

IAVI conducts clinical trials, observational epidemiology, and socio-behavioral research that informs the design of vaccine candidates and other prevention modalities. This work also provides important data for future efficacy trials to prevent HIV and other diseases of global public health significance. IAVI works with academic, government, foundation, and community-based partners to conduct this research.

IAVI’s network of clinical research partners in sub-Saharan Africa, India, and the U.K. play a central role in our clinical research.

IAVI supports the development of in-country scientific and technical expertise and leadership needed to conduct research at the highest ethical and scientific standards. IAVI also implements the concepts of Good Participatory Practice Guidelines to ensure community engagement throughout the research process.

IAVI’s key clinical research activities:
- Test novel vaccines and antibodies from preclinical research through Phase I-III clinical trials. This includes products against HIV, SARS-CoV2, tuberculosis, Lassa fever, snakebite, and others.
- Prepare to execute efficacy trials in at-risk populations through supportive epidemiology and capacity building, as well as stakeholder and community engagement.
- Develop in-country scientific capacity and leadership in the HIV research field, including HIV vaccine design and development through a wide range of collaborative and education programs.

Population(s) Served

IAVI advocacy work engages policymakers, scientists, activists, civil society organizations, influencers, community representatives, and stakeholders across the world to ensure that necessary resources and policies can sustain local, regional, and global support for vaccine development and new biomedical prevention approaches. IAVI recognizes that these approaches must reflect regional realities and priorities essential to ending AIDS, tuberculosis (TB), and emerging infectious diseases (EIDs) as well as addressing other unmet global health challenges. IAVI’s advocacy partners — from the community to the global level — mobilize a comprehensive response to disease prevention while ensuring decision-makers have the information and evidence to make informed choices about supporting global health solutions. This work has forged the path for HIV vaccines to be listed as national health research priorities in many countries where the organization works. IAVI, in partnership with the Uganda AIDS Commission, has also developed guidelines and a road map for delivering HIV and AIDS services in vulnerable Ugandan fishing communities. These national commitments translate into increased domestic support for strengthening research and regulatory facilities, as well as inclusive and effective health policies.

IAVI’s careful and informed approach to community engagement is essential to conduct safe and ethical HIV, TB and EID research in a way that avoids the potential for social harm such as discrimination, gender-based violence and stigma to study participants, especially those most vulnerable, including adolescent women and young girls, men who have sex with men, transgender women, and fishing communities. The IAVI model for community engagement continues to demonstrate that many marginalized and vulnerable communities are accessible and, with careful outreach initiatives, are eager to participate in potentially lifesaving scientific research. Activities such as India’s experiential learning, interactive theatre, and creative arts-based approaches demystify clinical trials for potential participants. Such work is essential for ensuring a fully informed and balanced representation of key populations in clinical trials.

Population(s) Served
People with HIV/AIDS
People of African descent
People with HIV/AIDS
People of African descent
People with HIV/AIDS
People of African descent

Where we work

Our results

SOURCE: Self-reported by organization

How does this organization measure their results? It's a hard question but an important one.

Epidemiology studies conducted that informed the design of HIV vaccine efficacy trials, improving future accessibility and acceptability of final product

This metric is no longer tracked.
Totals By Year
Population(s) Served

People with HIV/AIDS

Related Program

Discovery

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

IAVI-sponsored replicating VSV vector candidates advanced in novel portfolio toward clinical development

This metric is no longer tracked.
Totals By Year
Population(s) Served

People with diseases and illnesses

Related Program

Discovery

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Clinical research partners in Africa and India, including 11 state-of-the-art clinical research center partners with 12 GCLP-accredited laboratories capable of conducting clinical research at international standards.

This metric is no longer tracked.
Totals By Year
Population(s) Served

People with diseases and illnesses

Related Program

Discovery

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Scientists in LMICs trained in GCP and GCLP to international standards for conducting clinical trials

This metric is no longer tracked.
Totals By Year
Population(s) Served

People with diseases and illnesses

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

National and regional policies included HIV vaccine research, resulting in enhanced local ownership and an improved environment for research with at-risk populations.

This metric is no longer tracked.
Totals By Year
Population(s) Served

People with diseases and illnesses

Related Program

Discovery

Type of Metric

Output - describing our activities and reach

Direction of Success

Increasing

Projects managed by the IAVI Product Development Center since its establishment in 2013, as an integrated platform to advance promising concepts from bench to clinic

This metric is no longer tracked.
Totals By Year
Population(s) Served

People with diseases and illnesses

Related Program

Discovery

Type of Metric

Outcome - describing the effects on people or issues

Direction of Success

Increasing

Phase I/II trials supported by IAVI’s Product Development Center to assess external vaccine candidates and biologics.

This metric is no longer tracked.
Totals By Year
Population(s) Served

People with diseases and illnesses

Related Program

Discovery

Type of Metric

Outcome - describing the effects on people or issues

Direction of Success

Increasing

Number of research or policy analysis products developed, e.g., reports, briefs

This metric is no longer tracked.
Totals By Year
Population(s) Served

Adolescents, Young adults, People with diseases and illnesses

Related Program

Discovery

Type of Metric

Outcome - describing the effects on people or issues

Direction of Success

Holding steady

Context Notes

Scientific papers published by IAVI and partners

Number of media citations of advocate research or products

This metric is no longer tracked.
Totals By Year
Population(s) Served

People with diseases and illnesses

Related Program

Discovery

Type of Metric

Outcome - describing the effects on people or issues

Direction of Success

Increasing

Context Notes

Includes social media

Evidence demonstrating impact of research on gender, equity and the most vulnerable (through case studies)

This metric is no longer tracked.
Totals By Year
Population(s) Served

People with HIV/AIDS

Related Program

Discovery

Type of Metric

Outcome - describing the effects on people or issues

Direction of Success

Holding steady

Context Notes

Number of other open access, quality assured knowledge products produced and disseminated (e.g.,

Value of co-funding for IAVI programmes leveraged from nongovernment sources

This metric is no longer tracked.
Totals By Year
Population(s) Served

People with diseases and illnesses

Related Program

Discovery

Type of Metric

Outcome - describing the effects on people or issues

Direction of Success

Decreasing

Context Notes

Estimated total - HIV only.

Goals & Strategy

SOURCE: Self-reported by organization

Financials

IAVI
lock

Unlock financial insights by subscribing to our monthly plan.

Subscribe

Unlock nonprofit financial insights that will help you make more informed decisions. Try our monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights?
Learn more about GuideStar Pro.

Operations

The people, governance practices, and partners that make the organization tick.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

lock

Connect with nonprofit leaders

Subscribe

Build relationships with key people who manage and lead nonprofit organizations with GuideStar Pro. Try a low commitment monthly plan today.

  • Analyze a variety of pre-calculated financial metrics
  • Access beautifully interactive analysis and comparison tools
  • Compare nonprofit financials to similar organizations

Want to see how you can enhance your nonprofit research and unlock more insights? Learn More about GuideStar Pro.

IAVI

Board of directors
as of 8/17/2021
SOURCE: Self-reported by organization
Board co-chair

Dr. Eric Goosby

University of California, San Francisco


Board co-chair

Anne VanLent

AMV Advisors

Anne VanLent

President, AMV Advisors

Marijke Wijnroks

Chief of Staff, The Global Fund to Fight AIDS, Tuberculosis and Malaria

Linda-Gail Bekker

Deputy Director, Desmond Tutu HIV Centre

David Blumberg

Vice President, Teva Global Operations and Portfolio Compliance, Teva Pharmaceuticals

Jim Connolly

Former President and CEO of Aeras

Mark Dybul

Faculty Co-Director of the Center for Global Health Quality and Professor in the Department of Medicine, Georgetown University Medical Center

Robert Goldberg

Chief Operating Officer, Barnard College

Eric Goosby

Director, Center for Implementation Sciences, Global Health Sciences, at the University of California, San Francisco

John Nkengasong

Director, Africa Centres for Disease Control and Prevention

Francine Ntoumi

Research Group Leader, Institute for Tropical Medicine, University of Tübingen

John Shiver

Senior Vice President of Global Vaccine R&D, Sanofi Pasteur

Anne Simonds

Board/CEO Leadership Adviser, Global Leader of Health, Development and Social Enterprise, Spencer Stuart

Rajeev Venkayya

President, Global Vaccine Business Unit, Takeda Pharmaceuticals

Board leadership practices

SOURCE: Self-reported by organization

GuideStar worked with BoardSource, the national leader in nonprofit board leadership and governance, to create this section.

  • Board orientation and education
    Does the board conduct a formal orientation for new board members and require all board members to sign a written agreement regarding their roles, responsibilities, and expectations? Yes
  • CEO oversight
    Has the board conducted a formal, written assessment of the chief executive within the past year ? Yes
  • Ethics and transparency
    Have the board and senior staff reviewed the conflict-of-interest policy and completed and signed disclosure statements in the past year? Yes
  • Board composition
    Does the board ensure an inclusive board member recruitment process that results in diversity of thought and leadership? Yes
  • Board performance
    Has the board conducted a formal, written self-assessment of its performance within the past three years? No

Organizational demographics

SOURCE: Self-reported; last updated 8/17/2021,

Who works and leads organizations that serve our diverse communities? GuideStar partnered on this section with CHANGE Philanthropy and Equity in the Center.

Leadership

The organization's leader identifies as:

Gender identity
Male

The organization's co-leader identifies as:

Gender identity
Female

Race & ethnicity

No data

Gender identity

No data

 

No data

Sexual orientation

No data

Disability

No data